Curriculum Vitae. Elizabeth Donaghey MSN, ANP, CLNC
|
|
- Jayson Nichols
- 5 years ago
- Views:
Transcription
1 Curriculum Vitae Elizabeth Donaghey MSN, ANP, CLNC PRESENT POSITIONS: Genesis Clinical Research and Consulting, LLC President, CEO and Clinical Director Donaghey & Associates, LLC Legal Nurse Consulting Genesis Health Services WORK TELEPHONE: Genesis Clinical Research, LLC Donaghey & Associates, LLC STATE LICENSURE: Massachusetts Rhode Island CLNC certified EDUCATION: School Date Graduated Degree Somerset High School 1975 College Prep Somerset, MA University of Massachusetts 1979 BSN North Dartmouth, MA Simmons College 1997 MSN/ANP Boston, MA Vicki Milazzo Institute 2010 CLNC BOARD CERTIFICATIONS: ANCC certified Adult Nurse 1997-present # Practitioner NACLNC certified member 6/2010-present
2 PROFESSIONAL EXPERIENCE: 06/10 - Present Donaghey & Associates, LLC Certified Legal Nurse Consultant 373 New Boston Rd Fall River, MA /09 06/10 Nurse Practitioner/Urgent Care Westport Family Medicine Center 827 Main Road Westport, MA /09 Present Genesis Clinical Research/Pharmaceutical Trials Owner, President and Clinical Director Fall River, Ma /04 12/09 Infinity Medical Research/Pharmaceutical Trials Owner, Vice President and Director of Operations N. Dartmouth, MA /02-12/03 JM Clinical Trials/Pharmaceutical Trials SubInvestigator and Consultant 06/02 06/07 New Bedford Medical Associates Adult Nurse Practitioner/Pulmonary Medicine, Adult Medicine/Geriatrics Long Term Care North Dartmouth, MA and Swansea, MA 12/00 02/02 Truesdale Cardiology, Inc Adult Nurse Practitioner/Cardiology Fall River, MA 8/98 07/00 University Medical Group Adult Nurse Practitioner/Cardiology 50 Maude St. Providence, RI Salve Regina University Adjunct Faculty Nursing Dept. Newport, RI and Rhode Island Hospital Rhode Island Hospital Division of Cardiology Clinical Research Coordinator, Providence, RI Rhode Island Hospital, Staff Nurse Intermediate Coronary Care Unit
3 Staff Builders, Staff Nurse, per diem Mystic, CT/ Long Term Care, Geriatrics State University of NewYork, Staff Nurse/Med-Surg Stony Brook Hospital, Stony Brook, NY Morton Hospital, Staff Nurse Medical/Surgical, Cardiology Taunton, MA Boston University Medical Center, Staff Nurse Medical/Surgical Nursing Boston, MA PRESENTATIONS AND PUBLICATIONS: 1. Donaghey EB: Alzheimer s Disease: The latest research and treatment. Presented at Simmons College 11/ Donaghey EB, Terry PA: Dependent Care, Caregiver Burden and Self Care Agency Experiences of the Care Partner in the Cooperative Care Setting at Rhode Island Hospital. Masters Thesis: Presented at Simmons College Annual Research Forum 6/ Donaghey EB: Endocrinopathies in the Elder: When the Diagnosis is Missed. Manuscript: 12/ Donaghey EB, Leaf, ML: Utilization of Primary Care Services by the Homeless Residents at the Pine Street Inn: A Needs Assessment. Presented at Simmons College 6/97. CLINICAL RESEARCH EXPERIENCE: 1. A phase III, open label, outpatient extensions study to assess the long-term safety of XXX in adult primary insomnia patients with sleep maintenance difficulties. Sub-investigator 2. A randomized, double-blind, multi center study to evaluate the tolerability and effectiveness of XXX 90 mg qd vs XXX 50 mg tid in patients with osteoarthritis. Sub-investigator 3. A four-arm study comparing the analgesic efficacy and safety of XXX and doses of 100 mg, 200 mg, 300 mg and placebo for the treatment of pain due to osteoarthritis of the knee. Sub-investigator 4. A randomized, double-blind, placebo-controlled, parallel group, fixed dose, multi center study of weight reducing effect and safety of XXX in obese patients with type two diabetes. Sub-investigator
4 5. Beta Energy Restenosis Trial. A Phase II, randomized, multicenter study to investigate the effect of beta radiation on the restenosis rate of patients post coronary intervention. Clinical Research Coordinator 6. Dynamic Registry of Percutaneous Coronary Intervention. Clinical Research Coordinator. 7. Evaluation of the XXX Stent for Restenosis in Native Arteries. CRC 8. XXX Intracoronary Stent Versus XXX Stent for Elective Use In Denovo Lesions in Native Coronary Arteries. CRC 9. Evaluation of XXX on Restenosis Rates Post Percutaneous Transluminal Coronary Angioplasty in Denovo Lesions. CRC 10. Intraluminal vs Intramural Local Heparin Delivery with The XXX Catheter Prior to Stent Implantation. CRC 11. A double-blind, multicenter study to evaluate the safety and efficacy of aspirin vs coumadin post stent. CRC 12. An evaluation of Rotational Atherectomy post PTCA. CRC 13. A randomized, double blind trial evaluating the Vein Graft Angio-Jet System in patients with total coronary occlusions of thrombus. CRC 14. A Phase II, double blind placebo controlled study to assess the effect of intracoronary and multiple intravenous administration of XXX on exercise tolerance in adults with viable but underperfused myocardium. CRC 15. Effect of XXX on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease. A 52- Week, Multicenter, Double-Blind Study with 500 mg. XXX Once Daily Versus Placebo-(ALTANA Pharma AG) (2004) (Phase 3) 16. A Randomized, Double-Blind Placebo-Controlled, Flexible Dose Study Of The Efficacy and Safety of XXX in Comparison To XXX in Patients With Postherpetic Neuralgia. (Forest Research Institute) (2004) (Phase 2) 17. An Epidemiologic Study of XXX: Evaluating Clinical Effectivness And Long-Term Safety in Patients with Moderate to Severe Asthma (Genetech, Inc) (2004) (Phase 4) 18. A Phase 3, Randomized, Three-Arm, Double-blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of XXX in Combination with XXX Compared to XXX in Combination with XXX in
5 Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on XXX Therapy Alone (Bristol-Myers Squibb Company) (2004) (Phase 3) 19. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of XXX Compared to Placebo in the Treatment of Patients with Type 2 Diabetes Mellitus (Takeda Pharmaceuticals) (2004) (Phase 3) 20. A Phase III Pivotal, Multi-center, Double-Blind, Randomized, Placebo- Controlled Mono-therapy Study of XXX for Treatment of Fibromyalgia (Forest Research Institute) (2004) (Phase 3) 21. A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Clinical Health Outcomes of XXX versus XXX in Outpatients with Community-Acquired Lower Respiratory Tract Infections (Aventis,Inc.) (2004) (Phase IV). 22. Pharmacogenomic Sample Collection from Subjects with Type 2 Diabetes Treated with XXX or XXX (Perlegen Science, Inc.) (2005) 23. A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients with Anemia of Chronic Disease (ACD) Receiving XXX (Ortho-Biotech) (Phase 2) (2005) 24. A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes In Physical Function in Elderly Patients with Idiopathic Anemia (IAA) Receiving XXX (Ortho-Biotech) (Phase 2) (2005) 25. A Randomized, Double- blind, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of XXX (BMS ) Compared to XXX In Subjects with Type 2 Diabetes who Have Inadequate Glycemic Control (Bristol-Myers Squibb) (Phase 3) (2005) 26. An Extension Study/ A Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Monotherapy Study of XXX for Treatment of Fibromyalgia (Forest Research Laboratories) (Phase III) (2005) 26. A Two-Arm Study Comparing the Analgesic Efficacy and Safety of XXX Once-a-Day vs Placebo for the Treatment of Pain Due to Osteoarthritis (Labopharm) (Phase III) (2005) 27. Double-Blind, Multi-Center, Randomized, Parallel-Group, 16 Week Study of 400 or 1600 mg/day XX Administered Orally Once-A-Day with or without a Low Calorie Diet Lead-in in Obese Males and Females (Shionogi USA, Inc) (Phase III) (2005)
6 28. A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous XXX with Placebo in Patients with Acute Asthma (MERCK) (Phase III) (2005) 30. A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial of XXX Twice Daily in Patients with Fibromyalgia (Pfizer) (Phase III) (2005) 31. A 12-Week, Open-Label Safety Trial of XXX in Patients with Fibromyalgia. (Pfizer) (Phase III) (2005) 32. Effect of XXX on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease- A 52-Week, Double-blind Study with 500 mcg XXX Once Daily versus Placebo (ALTANA) (Phase III) (2006) 33. A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of XXX Versus XXX in patients with Mixed Hyperlipidemia. (MERCK) (Phase III) (2006) 34. A randomized, double-blind, double-dummy, placebo-controlled, 4x4 factorial design trial to evaluate XXX 20, 40 and 80 mg tablets in combination with XXX 2.5, 5 and 10 mg capsules after eight weeks of treatment in patients with Stage I or II hypertension, with an ABP sub-study (Boeringer Ingelheim) (Phase III) (2006) 35. Open-Label Extension of Initial 16-Week Proof-of-Concept Study to Continue Administration of XXX Orally Once-A-Day for 6 Additional Months (i.e., 28- weeks) in Obese Males and Females (Shionogi) (Phase 2) (2006) 36. A Randomized, double-blind, parallel-group, placebo-controlled, multicenter study evaluating the efficacy and safety of three doses of XXX in abdominally obese patients with atherogenic dyslipidemia (sanofi-aventis) (Phase 3) (2006) 37. A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of XXX in Subjects with Moderate to Severe Persistent Asthma Who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists (Genetech) (Phase 3) (2006) 38. A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8- Week Study to Evaluate the Efficacy and Safety of XXX When Initiated at the Start of the School year in Pediatric Patients With Chronic Asthma (Merck) (Phase 3) (2006) 39. A Phase III, Multi-center, Open-Label, Extension Study of XXX for the Treatment of Fibromyalgia (Forest Research Laboratories) (Phase 3) (2006) 40. A randomized, double-blind, double-dummy, placebo-controlled, 3x4 factorial design trial to evaluate XXX 20 and 80 mg tablets in combination with XXX 1.25, 10, and
7 20 mg capsules after eight weeks of treatment in patients with stage I or II hypertension, with an ABPM sub-study (Boehringer Ingelheim) (Phase 3) (2006) 41. Multicenter, Randomized, Double-Blind Study, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of XXX (dosed as coadministered XXX and XXX Tablet) Versus XXX in Patients with Mixed Hyperlipidemia (MERCK) (Phase 3) (2006) 42. A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of XXX in the Treatment of Obese Subjects (Pfizer) (Phase 3) (2006) 43. Lipid Treatment Assessment Project (Pfizer) (Phase: Observational Survey) (2006) 44. Prospective Observational Study to Evaluate Physical Performance and Quality of Life in Older Long Stay Nursing Home Residents with Chronic Kidney Disease with and without Anemia (Omnicare) (Phase 3) (2006) 45. Efficacy and Safety of Inhaled Human Insulin (EXUBERA) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial (Pfizer) (Phase 3) (2007) 46. A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of XXX plus XXX Alone or XXX Alone in Subjects with Type 2 Diabetes (Takeda Pharmaceuticals) (Phase 3) (2007) 47. A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of XXX in Subjects with Type 2 Diabetes. (Takeda Pharmaceuticals) (Phase 3) (2007) 48. A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with XXX in Subjects with Active Ulcerative Colitis (UC) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy. (Bristol-Myers Squibb) (Phase 3) (2007) 49. A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate The Clinical Efficacy and Safety of Induction and Maintenance Therapy with XXX in Subjects with Active Crohn s Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy. (Bristol-Myers Squibb)(Phase 3) (2007) 50. Double Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0 or 1600 mg/day of XXX Administered Orally Once Daily with an Initial 6-Week Low Calorie Diet In Obese Males and Females (Shionogi) (Phase 3) (2007)
8 51. XXX Add- on Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of XXX in Patients with Postherpetic Neuralgia (PHN) Concomitantly Treated with XXX. (Pfizer) (Phase 2) (2007) 52. A Phase III Pivotal, Multi-center, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of XXX for the treatment of Fibromyalgia (Forest Laboratories) (Phase 3) (2007) 53. A randomized, double-blind, double-dummy, placebo-controlled, 3x4 factorial design trial to evaluate XXX 20 and 80 mg tablets in combination with XXX 1.25, 10, and 20 mg capsules after eight weeks of treatment in patients with stage I or II hypertension, with an ABPM sub-study (Boehringer Ingelheim) (Phase 3) (2006) 54. Multicenter, Randomized, Double-Blind Study, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of XXX (dosed as coadministered XXX and XXX Tablet) Versus XXX in Patients with Mixed Hyperlipidemia (MERCK) (Phase 3) (2006) 55. A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of XXX in the Treatment of Obese Subjects (Pfizer) (Phase 3) (2006) 56. Lipid Treatment Assessment Project (Pfizer) (Phase: Observational Survey) (2006) 57. Prospective Observational Study to Evaluate Physical Performance and Quality of Life in Older Long Stay Nursing Home Residents with Chronic Kidney Disease with and without Anemia (Omnicare) (Phase 3) (2006) 58. Efficacy and Safety of Inhaled Human Insulin (EXUBERA) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial (Pfizer) (Phase 3) (2007) 59. A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of XXX plus XXX Alone or XXX Alone in Subjects with Type 2 Diabetes (Takeda Pharmaceuticals) (Phase 3) (2007) 60. A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of XXX in Subjects with Type 2 Diabetes. (Takeda Pharmaceuticals) (Phase 3) (2007)
9 61. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of XXX Administered Once Daily In Patients with Fibromyalgia. (Pfizer) (Phase 3) (2007) 62. A Randomized, Double-Blind, Parallel-Group, Multi-Center, Multinational Study to Assess Glycemic Control with Rimonabant In Comparison with Glimepiride over 1 Year in Overweight/Obese Type 2 Diabetic Patients Not Adequately Controlled with Metformin. (Sanofi Aventis) (Phase 3) (2007) 63. Double Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0 or 1600 mg/day of XXX Administered Orally Once Daily with an Initial 6-Week Low Calorie Diet In Obese Males and Females (Shionogi) (Phase 3) (2007) 64. XXX Add- on Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of XXX in Patients with Postherpetic Neuralgia (PHN) Concomitantly Treated with XXX. (Pfizer) (Phase 2) (2007) 65. A Phase III Pivotal, Multi-center, Double-blind, Randomized, Placebo- Controlled Monotherapy Study of XXX for the treatment of Fibromyalgia (Forest Laboratories) (Phase 3) (2007) 66. A Study of the Therapeutic Equivalency of XXXmcg and 200 mcg Inhalers in Corticosteroid-Dependent Subjects with Moderate Asthma. (Schering-Plough) (2007) 67. A Randomized Double-Blind-Dummy, Placebo-Controlled, Parallel- Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of XXX Inhalation Powder Administered Once Daily and XXX Inhalation Powder Twice Daily Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy. (GlaxoSmith Kline) (Phase 2b) (2007) 68. A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of XXX Inhalation Powder Once Daily and Fluticasone Proionate Inhalation Powder 250 mcg Twice Daily Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose ICS Therapy. (GlaxoSmith Kline) (Phase 2b) (2007) 69. A Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid
10 on Niaspan-Induced Flushing in Subjects with Dyslipidemia. (Abbott) (Phase 3) (2007) 70. A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof of Concept Study of the Analgesic Effects of XXX in Adult Patients with Post-Herpetic Neuralgia. (Pfizer) (2007) 71. A Randomized Event and Safety Open-Label NSAID Study (GI Reasons) A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety of XXX Compared with Non-Selective Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) in Osteoarthritis Patients. (Pfizer) (Phase 4) (2007) 72. A Twelve Week, Randomized, Double-Blind, Double-Dummy, Placebo- Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy And Safety of XXX in Comparison to XXX in Patients with Overactive Bladder. (Pfizer) (Phase 3b/4) (2007) 73. A Randomized, Double-Blind Placebo Controlled Trial of [S,S]- Reboxetine in Patients with Chronic Painful Diabetic Peripheral Neuropathy. (Pfizer) (Phase 2b) (2007) 74. A Randomized Double-Blind, Placebo- and Active Control, Parallel-arm, Phase 3 Trial with Controlled Adjustment of Dose To Evaluate the Efficacy and safety of XXX Extended-Release (ER) in Subjects with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee. (Johnson &Johnson) (2007) 75. Open-Label Extension, single-arm, Flexible-Dosing, Phase 3 Trial with XXX in Subjects with Moderate to Severe Chronic Pain. (Johnson & Johnson) (2007) 76. A Double Blind, Randomized, Placebo-Controlled Study to evaluate the Efficacy and Safety of XXX When Co-Administered with Amlodipine in Subjects with Essential Hypertension. (Takeda) (2007) 77. A Randomized Double-Blind, Placebo-Controlled, Parallel Group, 6-week Clinical Study to Assess the Effect of XXX on Exercise Endurance and Lung Hyperinflation in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease. (Forest Research Institute) (2008) 78. A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Outpatient Trial of XXX in Adults with Nonrestorative Sleep. (Pfizer) (2008)
11 79. An Observational Surveillance Study to Monitor the Occurrence of Rotavirus Acute Gastroenteritis Among a Cohort of Subjects Residing in Several Long Term Care Facilities in the United States. (Merck) (2008) 80. Open-Label Extension (OLE) Safety and Efficacy Study of Velneperit (S-2367) Following the Year-Long Controlled Clinical Trials of S-2367 in Obese Males and Females. (Shionogi) (2008) 81. A Multi- Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Impact on Health-Related Quality of Life of Levocetirizine 5 mg. Once Daily Given for Two Weeks in Subjects 18 years of Age and Older with Seasonal Allergic Rhinitis. (UBC) (2008) 82. A Randomized, Double-Blind, Placebo- and Active- Controlled, Parallel-arm, Multicenter, Study In Subjects With End- Stage Joint Disease to Compare the Frequency Of Constipation Symptoms in Subjects Treated With Tapentadol IR and Oxycodone IR Using a Bowel Function Patient Diary (Johnson & Johnson) (2008) 83. A Multi-Center, Randomized, Open-Label, Controlled Study to Evaluate the Safety, Tolerability, and the Efficacy of Milnacipran When Added to Pregablin in the Treatment of Fibromyalgia. (Forest Research Institute) (2008) 84. General Effect of Liraglutide In Obesity Treatment - Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities. - A randomized, double-blind, placebo controlled, parallel group, multi-centre, multinational trial with stratification of subject to either one or three years of treatment based on pre-diabetes status at randomization. (Novo-Nordisk) (2008) 85. A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide when Used in Combination with Metformin in Subjects with Type 2 Diabetes (Takeda) (2009) 86. A Randomized, Double- Blind, Placebo-Controlled, 2 arm, Parallel Group, Multi-Center, Study With a 24- Week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Piolglitazone in Patients with Type II Diabetes not Adequately Controlled By Pioglitazone. (Sanofi-Aventis 2009) 87. Telmisartan 80 mg plus Amlodipine 10 mg fixed-dose combination tablet Study versus Amlodipine 10 mg over-encapsulated tablets or Telmisartan 80 mg tablets as first line therapy in patients with severe Hypertension: a Phase III, 8 week, randomized, doubleblind, double-dummy, forced titration comparison [TEAMSTA severe HTN] (Boehringer Ingelheim) (2009)
12 88. A Long Term, Randomized, Double-Blind, Extension Study of the Safety and Tolerability and Efficacy of XXX at Two Dose Levels When Administered to Patients with Moderate to severe COPD. 89. Efficacy and Safety of XXX at Three Dose Levels ( 200microgram twice daily, and 400 micrograms twice daily, 200 microgram once daily ) vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease ( COPD ). 90. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Discontinuation Study to Evaluate the Durability of Effect of Milnacipran for the treatment of Fibromyalgia in Patients With Long Term Milnacipran Treatment. 91. A Prospective, Randomized Double-Blind Study of the Efficacy of Xolair in Atopic Asthmatics with Good Lung Capacity Who Remain Difficult to Treat. 92. A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study Evaluating the Efficacy and Safety of Tanezumab for the Treatment of Moderate to Severe Pain Associated With Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) (Pfizer) (2009) 93. A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects with Euvolemic Hyponatremia (Cardiokine) (2009) 94. A Long-Term, Randomized, Double-blind Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dosage Levels When Administered to Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (Forest) (2009) 95. A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen. (Pfizer) (2010) 96. A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose (Forest) (2009) 97. A Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitizar to Reduce Cardiovascular Risk in Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)
Paula J. Lane, M.D. Albuquerque Neuroscience, Inc. 101 Hospital Loop NE, Suite 209 Albuquerque, NM 87109
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: Paula J. Lane, M.D. Albuquerque
More informationCLINICAL RESEARCH EXPERIENCE: PATRICK H. PETERS, JR. M.D.
CLINICAL RESEARCH EXPERIENCE: PATRICK H. PETERS, JR. M.D. PRINCIPAL INVESTIGATOR 1989 U.S. Multicenter Phase III: Study Of a Novel NSAID In Oseteoarthritis 1998 U.S. Multicenter Osteoporosis Trial. 1998
More informationCurriculum Vitae, Joseph J. Savon, M.D.
CONTACT INFORMATION: Joseph J. Savon, M.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCurriculum Vitae, Edward H. Ortiz, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: FutureSearch Trials
More informationCurriculum Vitae, Ward Jackson Paine, M.D. Ward Jackson Paine, M.D. Exemplar Research, Inc Mileground Road Morgantown, WV 26505
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Ward Jackson Paine,
More informationCurriculum Vitae, Steven H. Reynolds, D.O. Steven H. Reynolds, D.O. Collaborative Neuroscience Network, LLC.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationCurriculum Vitae, Michael A. Hassman, D.O.
CONTACT INFORMATION: Michael A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCurriculum Vitae, Michael A. Hassman, D.O.
CONTACT INFORMATION: Michael A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCURRICULUM VITAE. RESEARCH SITE NAME/ ADDRESS: Main Office: EDUCATION/TRAINING: BOARD CERTIFIED: BOARD CERTIFIED/ELIGIBLE NAME: TITLE:
CURRICULUM VITAE SIGNATURE: NAME: TITLE: Roy C, Springer, MD Principal Investigator DATE: DATE UPDATED: April 2016 RESEARCH SITE NAME/ ADDRESS: Main Office: MD Strategies Research Centers 6280 Jackson
More information09/84-06/88 BA, Chemistry Robert D. Clark Honors College, University of Oregon, Eugene, OR
CONTACT INFORMATION: Drissana T Tran, M.D. Oregon Center for Clinical Investigations, Inc. 702 Church Street NE Salem, OR 97301 Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916)
More informationCurriculum Vitae, John Douglas Hudson, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: John Douglas Hudson, M.D.
More informationAnesthesiology University of North Carolina, Chapel Hill, NC (Residency)
Edward M. Tavel, Jr. M.D. Pain Specialists of Charleston Clinical Trials of South Carolina 2695 Elms Plantation Blvd Suite A and Suite D Charleston, SC 29406 Clinic: 843-818-1181 Research: 843-725-5067
More informationCurriculum Vitae, Michael J. Downing, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com PROFESSIONAL AFFILIATIONS: Michael
More informationRobert J. Cooper, M.D., F.A.C.E., F.A.C.P. 20 Cherry Lane Longmeadow, MA Phone: (413) Fax: (413)
Robert J. Cooper, M.D., F.A.C.E., F.A.C.P. 20 Cherry Lane Longmeadow, MA 01106 Phone: (413) 387-5971 Fax: (413) 567-3950 ShaRobCoop@aol.com PROFESSIONAL EXPERIENCE: New England Endocrine & Thyroid Center,
More informationANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE
ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE PERSONAL DATA: DATE OF BIRTH: April 23, 1959 PLACE OF BIRTH: Amalapuam, A.P., India EDUCATION: COLLEGE: Andhra Christian College BS Degree Andhra Loyola College
More informationPROFESSIONAL MEMBERSHIPS
June 2012 January 2014 October 2009 May 2012 Staff Rheumatologist, Diagnostic Clinic, Clearwater, FL Staff Rheumatologist, Arthritis Associates, Palm Harbor, FL 2008 2012 Co-Investigator, Arthritis Research
More informationCurriculum Vitae, Anand Mehta, M.D. Anand Mehta, M.D. Pacific Research Partners, LLC 1611 Telegraph Avenue, Suite 1550 Oakland, CA 94612
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationEdward M. Tavel, Jr. M.D. Pain Specialists of Charleston 2695 Elms Plantation Blvd Suite A and Suite D Charleston, SC 29406
Edward M. Tavel, Jr. M.D. Pain Specialists of Charleston 2695 Elms Plantation Blvd Suite A and Suite D Charleston, SC 29406 Clinic: 843-818-1181 Research: 843-725-5067 Fax: 843-818-1145 Education 1981-1985
More informationUniversity of North Carolina, Chapel Hill, NC (Chief Resident)
Edward M. Tavel, Jr. M.D. Pain Specialists of Charleston 2695 Elms Plantation Blvd Suite A and Suite D Charleston, SC 29406 Clinic: 843-818-1181 Research: 843-725-5067 Fax: 843-818-1145 Education 1981-1985
More informationCurriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationCurriculum Vitae, Conrad O. Beckles, M.S., L.M.H.C., Ph.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Conrado Oscar Beckles,
More informationCurriculum Vitae, Nirav S. Patel, M.D. Nirav S. Patel, M.D. Collaborative Neuroscience Network, LLC.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationCurriculum Vitae, Carmen Zegarra, M.D. Carmen Zegarra, M.D. FutureSearch Clinical Trials, L.P Parkcrest Drive, Suite 300 Austin, TX 78731
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Carmen Zegarra, M.D. FutureSearch
More informationSUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84
CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:
More informationCurriculum Vitae Scott A. Wright, MD, FACC
Curriculum Vitae Scott A. Wright, MD, FACC Address: 1783 Troup Hwy Tyler, Texas 75701 Telephone: Office (903)-595-2283 Fax (903)-597-2238 Practice 2012-Present 2009-Present 2003-Present Center for Medical
More informationWest Virginia University School of Medicine, Morgantown, West Virginia
MARY CARROLL SHEMO, M.D., D.F.A.P.A. CURRICULUM VITAE Psychiatric Alliance of the Blue Ridge Office: (434) 984-6777 First Floor, Old Ivy Commons, 2496 Old Ivy Road, Suite 400 Fax: (434) 296-1412 22903-4895
More informationSummary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
More informationCurriculum Vitae, John Douglas Hudson, M.D.
John Douglas Hudson, M.D. FutureSearch Trials of Neurology and Sleep Lab 5508 Parkcrest Drive, Suites 300 & 310 Austin, TX 78731 Tel: (512) 380-9925 CONTACT INFORMATION: Site Selection and Information:
More informationPACIFIC RESEARCH NETWORK_ 3003 Fourth Avenue, San Diego, CA * (619) Ph. (619) Fax
PACIFIC RESEARCH NETWORK 3003 Fourth Avenue, San Diego, CA 92103 * (619) 294-4302 Ph. (619) 294-4867 Fax JOHN J. DORIA, M.D. EDUCATION 1958 Medical: Universidad Nationale de Mexico, Mexico, Degree: M.
More informationCurriculum Vitae, Nirav S. Patel, M.D. Nirav S. Patel, M.D. Collaborative Neuroscience Network, LLC Redondo Avenue, Suites 415 & 500
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationCURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA
Bruce D. Kohrman, M.D. 12305 SW 69 th Place Miami, Florida 33156 Telephone: (305) 903-8678 Fax: (305) 661-1672 CURRICULUM VITAE EDUCATION 1977 - B.S. Stanford University, Stanford, CA 1982 - M.D. Case
More informationDeborah R. Tunick, RN, CCRC Curriculum Vitae
CHESAPEAKE RESEARCH GROUP, LLC Deborah R. Tunick, RN, CCRC Curriculum Vitae EDUCATION: Undergraduate: Abilene Christian University Abilene, Texas Bachelor of Science in Nursing Minor in Child Psychology
More informationCurriculum Vitae, Glenn Michael Dempsey, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: Glenn Michael Dempsey,
More informationCURRICULUM VITAE. University of Columbia Missouri Department of Psychiatry and Neurology
CURRICULUM VITAE Rubén Bravo Valverde, M.D. Forensic and Geriatric Psychiatrist Centro Especializado de Psiquiatría 1995 Road 2 Suite 1209-1210 Bayamón, Puerto Rico 00959-1201 Telephones: (787) 786-0575/780-3752
More informationSUBURBAN LUNG ASSOCIATES, S.C. Eberle Medical Building, 800 Biesterfield road, Suite 510 Elk Grove Village, IL Sleep Group
SUBURBAN LUNG ASSOCIATES, S.C. Eberle Medical Building, 800 Biesterfield road, Suite 510 Elk Grove Village, IL 60007 NAME Kuljeet Kaur Gill M.D. Nickname: Kelly Address: Suburban Lung Associates SC 800
More informationCURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP
CURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP Business address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, Fl Phone: 941.951.3920 Fax: 941.951.3922 Prior business
More informationCurriculum Vitae, Glenn Michael Dempsey, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com Glenn Michael Dempsey, M.D. Albuquerque
More informationCurriculum Vitae, Glenn Michael Dempsey, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: Glenn Michael Dempsey,
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationInternal & Hospital Medicine #7001
Internal & Hospital Medicine #7001 Publications, presentations, and references available upon request. Contact Dora: dmancias@expertwitnessdoctors.com 512-689-6879 EDUCATION 1994 Internal Medicine Residency
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs January 201 DATE DAY TIME TOPICS January 04 January 11 January 1 January 25 9:00AM 9:00AM 9:00AM 9:00AM 1. Understanding Fibromyalagia 2. Diabetes
More informationCENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials DEPARTMENT OF MEDICINE (24)
CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials DEPARTMENT OF MEDICINE (24) Arthritis TITLE : A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019
January 2019 DATE DAY TIME TOPICS TOTAL January 03 1. Alcoholism 2. Nutrition for the Elderly 3. Uterine Fibroids 4. HIPAA 5.Arthritis 6. Childhood Obesity January 10 1. Understanding Epilepsy: Latest
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationChief Operating Officer North Star Medical Research, LLC
CURRICULUM VITAE Joann M. Berenda, AAB Chief Operating Officer North Star Medical Research, LLC 18660 Bagley Road, Building II, Suite 205 Middleburg Heights, OH 44130 Telephone: Fax: email: +01 440 234
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationRobert J. Cooper, M.D., F.A.C.E., F.A.C.P. 20 Cherry Lane Longmeadow, MA Phone: (413) Fax: (413)
Robert J. Cooper, M.D., F.A.C.E., F.A.C.P. 20 Cherry Lane Longmeadow, MA 01106 Phone: (413) 387-5971 Fax: (413) 567-3950 ShaRobCoop@aol.com PROFESSIONAL EXPERIENCE: Baystate Medical Center 3300 Main Street
More informationClinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)
, fully signed Clinical Trial Agreements (except grants) Sponsor Full name of the Hospital clinic where the is details of the January x x January x NightstaRx Ltd A Randomised, Open Label, Outcomes-Assessor
More informationChapter 4 Section 9.1
Surgery Chapter 4 Section 9.1 Issue Date: August 26, 1985 Authority: 32 CFR 199.4(c)(2) and (c)(3) 1.0 CPT 1 PROCEDURE CODES 33010-33130, 33140, 33141, 33200-37186, 37195-37785, 92950-93272, 93303-93581,
More informationR&D Pipeline (May 2006)
R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence
More informationCURRICULUM VITAE East Riverside Boulevard Rockford, IL 61114
CURRICULUM VITAE Name: Present Employer: David J. Dansdill, M.D., F.A.C.R. OrthoIllinois 5875 East Riverside Boulevard Rockford, IL 61114 Date Affiliated: January 2003 Date of Birth: July 25, 1958 Place
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationCognitive Research Corporation
Cognitive Research Corporation Contract Research Organization offering specialized expertise to fit the unique needs of each client Bobbie Theodore clinicaltrials@alliancesites.com An Alliance of Quality
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018
January 201 DATE DAY TIME TOPICS TOTAL January 04 1. Understanding Fibromyalagia 2. Diabetes and Cardiovascular Disease 3. Prostate Cancer 4. Hepatitis C 5. Understanding Hepatitis B January 11 1. Dysphagia
More informationKevzara (sarilumab) NEW PRODUCT SLIDESHOW
Kevzara (sarilumab) NEW PRODUCT SLIDESHOW Introduction Brand name: Kevzara Generic name: Sarilumab Pharmacological class: Interleukin-6 antagonist Strength and Formulation: 150mg/1.14mL, 200mg/1.14mL;
More informationIntegrative Medicine in Residency. Site Leader Responsibilities Sample Site Implementation Plans
Integrative Medicine in Residency Site Leader Responsibilities Sample Site Implementation Plans IMR Site Leader Responsibilities and Time Commitment!" #$%&$()*+$,-./*,$%)-/0-%*+$123(*%$).4$/56,%-7%(89
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationStudy Design: Prospective, Multicenter randomized, parallel-group, double blind, placebo controlled study.
Brand Name: Farxiga Generic Name: Dapagliflozin Manufacturer: Astra-Zenica Drug Class 1,2 : Antidiabetic agent, SGLT2 Inhibitor Uses: Labeled Uses 1,2,3,4 : Improving glycemic control in adults with type
More informationInflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union
Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,
More informationSponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationCurriculum Vitae, Corinna A. Gamez, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationOrganizational, or Other Financial Benefit None None None None None None. None None None None None None
Comprehensive Relationships With Industry and Other Entities AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non ST-Elevation Myocardial Infarction Measures Committee Jneid Hani, Chair Baylor
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationChapter 4 Section 9.1
Surgery Chapter 4 Section 9.1 Issue Date: August 26, 1985 Authority: 32 CFR 199.4(c)(2) and (c)(3) 1.0 CPT 1 PROCEDURE CODES 33010-33130, 33140, 33141, 33361-33369, 33200-37186, 37195-37785, 92950-93272,
More informationR&D Pipeline (November 2005)
R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)
More informationCurriculum Vitae, Roberta R. Ball, D.O., M.A., F.A.P.A., F.A.C.N.
CONTACT INFORMATION: Roberta R. Ball, D.O., M.A., F.A.P.A., F.A.C.N. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information:
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationMichael Keith Schrader, MD, FACP 6020 W. Parker Rd., Ste. 420 Center for Executive Medicine Plano, TX North Texas Medical Research
, FACP 6020 W. Parker Rd., Ste. 420 Center for Executive Medicine Plano, TX 75093 North Texas Medical Research 972-244-1300 voice mkschrader@texasmed.com 972-244-1381 fax www.texasmed.com November 30,
More informationGary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC
Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC 9420 Key West Ave, Suite 420, Rockville, MD 20850 2730 University Blvd, West, Suite 516, Wheaton,
More informationCOPD Research at the University of Maryland School of Maryland
COPD Research at the University of Maryland School of Maryland COPD Clinical Research Center A member of the National Heart Lung & Blood Institute National Institutes of Health Director: Steven M. Scharf,
More informationJuly 2011 Medical Update Information
July 2011 Medical Update Information Simvastatin (Zocor) new FDA restrictions FDA statement June 2011 Based on the SEARCH 7 year trial in patients who were considered stable after have had a heart attack.
More informationSub-Investigator - Center For Clinical Research Center For Clinical Research 35 Pearl Street, Suite 300 Brockton, MA Present
CURRICULUM VITAE: EMPLOYMENT: MARK T. CLAUS, M.D. Asthma & Allergy Physicians 35 Pearl Street, Suite 300 Brockton, MA 02301 1988 - Present Sub-Investigator - Center For Clinical Research Center For Clinical
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationDouglas N. Robins, M.D. Ameriderm Research
Curriculum Vitae Douglas N. Robins, M.D. Ameriderm Research Office Address: Leavitt Medical Associates of Florida (DBA) Advanced Dermatology and Cosmetic Surgery Ameriderm Research 4100 Southpoint Dr.
More informationPRI-MED UPDATES Long Beach, CA October 10-11, 2008 PROGRAM DIRECTORY
PRI-MED UPDATES Long Beach, CA October 10-11, 2008 PROGRAM DIRECTORY Accreditation Information Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME), which
More informationIroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults
Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed
More informationFamily Medicine Clerkship. Learning Prompts
Family Medicine Clerkship Learning Prompts 9 SYSTEMS & CONDITIONS Respiratory conditions................................. 1 COPD Asthma Infectious diseases.................................... 2 Sore throat
More informationCURRICULUM VITAE. NAME: Kyoo-Rok Han, M.D., Ph.D. (Professor) ADDRESS:
CURRICULUM VITAE NAME: Kyoo-Rok Han, M.D., Ph.D. (Professor) ADDRESS: Div. of Cardiology, Dept. of Internal Medicine College of Medicine, Hallym University, Kangdong Sacred Heart Hospital, 445 Kil-Dong,
More informationCURRICULUM VITAE. Andrea Marraffino, Ph.D.
CURRICULUM VITAE CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (866) 669-0234 Fax (208) 575-3169 Email: clinicaltrials@btheodore.com AFFILIATIONS: Florida Clinical
More informationCURRICULUM VITAE TELEPHONE NUMBER/FAX NUMBER: (732) / (732)
CURRICULUM VITAE NAME: PRESENT TITLE: Didier Demesmin, MD CEO and Medical Director, University Pain Medicine Center OFFICE ADDRESS: 59 Veronica Avenue, Somerset, NJ 08873 TELEPHONE NUMBER/FAX NUMBER: (732)
More informationADA Analyst Presentation Saturday 9 th June
ADA Analyst Presentation Saturday 9 th June Carlo Russo Senior Vice-President & Albiglutide Team Leader, GSK Property of GlaxoSmithKline Agenda Welcome & introduction to the Harmony Clinical Programme
More informationMITCHELL JAY RUBIN, M.D. FAAN (cell) Neurology Expert Witness Stroke tpa Emergency Neurology Telemedicine
Education University of Pennsylvania Philadelphia, Pennsylvania B. A. Summa Cum Laude 1976 Phi Beta Kappa 1977 Pi Gamma Mu (National Social Science Honor Society) 9/1977-5/1981 University of Pennsylvania
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationMEDICATION APPROPRIATENESS FOR THE AGING POPULATION. Building Partnerships for Successful Aging
MEDICATION APPROPRIATENESS FOR THE AGING POPULATION Building Partnerships for Successful Aging Learning objectives Appreciate complexities involved in making appropriate clinical decisions in older adults
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPATIENT HISTORY QUESTIONNAIRE
PATIENT HISTORY QUESTIONNAIRE The information requested in this questionnaire is very important. To give you the best care and to obtain your insurance approval, we must have complete answers. If you are
More informationHoward A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009
CONTACT INFORMATION: Howard A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More information